Japanese researchers announced on Monday the first attempt of a human with a type of stem cell to treat Parkinson's disease, building on earlier animal experiments.
Kyoto University's research team plans to inject five million induced pluripotent stem cells (iPSs) into each patient's brain in patient brains, the university said in a press release.
The iPS cells of healthy donors are being developed into dopamine-producing brain cells that are no longer present in Parkinson's disease patients.
Parkinson's disease is a chronic, degenerative neurological disorder that affects the motor system of the body and often causes shaking and shaking other movement difficulties
According to Parkinson's disease, about 1
at present Available therapies "improve symptoms without slowing or stopping the disease," says the foundation.
But the new research aims to actively reverse the disease.
The clinical trial of seven participants, ages 50 to 69, begins on Wednesday.
The folklore is observed by the patients two years after the operation.
The human study comes after a previous study with monkeys.
Researchers last year announced that primates with Parkinson's symptoms after the introduction of iPS cells again showed significant mobility in their brains.
They also confirmed that the iPS cells did not turn into tumors in the two years after the implant.
iPS cells are created by bringing mature, already specialized cells back into a juvenile state – in principle without cloning the need for an embryo.
These can be derived from the patient, resulting in less rejection while avoiding ethical concerns about removing cells from embryos.
The cells can be transformed into a number of different types of cells, and their use is a key sector of medical research.
Riken, a Japanese-backed research organization, led the world's first urgent need to implant iPS cells in 2014 to treat patients with age-related macular degeneration (AMD), a common medical condition that causes blindness in the elderly can lead.
Osaka University Also Schedules Heart Failure Clinical Trial
In the US, Duke University researchers said in January that they had, for the first time, succeeded in cultivating functioning human muscles from iPS cells in the laboratory.
Aggressive immune cells increase Parkinson's disease